{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXA&page=14", "query": { "intervention": "DEXA", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 359, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXA&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DEXA&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:40:57.097Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03763162", "title": "Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-01-17", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03763162" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" }, { "nct_id": "NCT04752163", "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "DS-1594b", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-25", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752163" }, { "nct_id": "NCT02352753", "title": "Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteogenesis Imperfecta" ], "interventions": [ { "name": "Denosumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 153, "start_date": "2015-06-24", "completion_date": "2022-03-26", "has_results": true, "last_update_posted_date": "2022-12-28", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 13, "location_summary": "Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352753" }, { "nct_id": "NCT02435251", "title": "Changes in Anthropometry Following Ambulatory Orthopaedic Surgery", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Knee Surgery", "Shoulder Surgery" ], "interventions": [ { "name": "dual energy X-ray absorptiometry", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "State University of New York at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Amherst, New York", "locations": [ { "city": "Amherst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435251" }, { "nct_id": "NCT05514990", "title": "Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pelareorep", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-10-07", "completion_date": "2027-08-22", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514990" }, { "nct_id": "NCT02512874", "title": "Does Pulmonary Rehabilitation Improve Frailty?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Disease, Pulmonary" ], "interventions": [ { "name": "Pulmonary Rehabilitation", "type": "OTHER" }, { "name": "Dynamometer", "type": "DEVICE" }, { "name": "DEXA", "type": "RADIATION" }, { "name": "Gait Speed Test", "type": "OTHER" }, { "name": "Activity Monitor", "type": "DEVICE" }, { "name": "Questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DEVICE", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-07-21", "completion_date": "2018-10-16", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02512874" }, { "nct_id": "NCT02704377", "title": "Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Carcinoma" ], "interventions": [ { "name": "Undergo HRV and wear accelerometer to assess therapy complications", "type": "OTHER" }, { "name": "Dual X-ray Absorptiometry", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 6, "start_date": "2016-05-08", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704377" }, { "nct_id": "NCT07083531", "title": "Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease", "Sickle Cell Trait" ], "interventions": [ { "name": "Healthy volunteers without SCT", "type": "OTHER" }, { "name": "Healthy volunteers with SCT", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UConn Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2022-08-23", "completion_date": "2025-08-23", "has_results": false, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07083531" }, { "nct_id": "NCT05561387", "title": "Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 510, "start_date": "2023-10-12", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-22T09:40:57.097Z", "location_count": 397, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05561387" } ] }